Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
about
βIII-Tubulin: biomarker of taxane resistance or drug target?Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centresEvaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.The impact of expression profiling on prognostic and predictive testing in breast cancer.High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer.Emerging issues in traditional Chinese medicine.MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.Controversies in breast cancer: adjuvant and neoadjuvant therapy.A systematic review of taxane-containing regimens for metastatic breast cancer.Taxanes for the treatment of metastatic breast cancer.Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.Quality of life and adjuvant systemic therapy for early-stage breast cancer.TLE3 as a candidate biomarker of response to taxane therapy.miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.Taxane benefit in breast cancer--a role for grade and chromosomal stability.Optimal adjuvant chemotherapy in breast cancer: selection of agents.Octa-ammonium POSS-conjugated single-walled carbon nanotubes as vehicles for targeted delivery of paclitaxelPolymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Collapsin response mediator protein 2 is involved in regulating breast cancer progression.Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands.A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.Preparation and Evaluation of Solid-Self-Emulsifying Drug Delivery System Containing Paclitaxel for Lymphatic Delivery
P2860
Q28284878-0A909059-7CCD-40C8-9C94-9BD1AC46707BQ33388534-C046503D-C5CC-4D62-AB34-9B8C3060ED7AQ33831109-039003E3-BC12-43FA-A205-2ED689453DD2Q34778630-51071EA0-674D-4692-A7A5-6738D322AB77Q35026994-9922B6EA-E9A8-4227-A5B7-E592C463D159Q35683522-E32FC908-D697-464D-BEBB-9A4B6D76EBEAQ35769768-AFEE8341-7281-44D8-9FA3-465F7DC8166DQ36028731-9DDC30E4-A0A9-4B93-B80E-9FFB04F3A434Q36118255-5303ABF0-395C-4204-A3E2-A3042CA858AEQ36157026-41291240-E93F-405E-9D2B-6798054CCA6CQ36163952-7AB6BB0E-56E2-4F9D-912A-90A953F76649Q36211570-351A6A71-6590-4D6D-A871-AB0C955FE036Q36364762-4EE7A87C-30D0-4762-B177-B4C771012E5BQ36475847-FAFF8CF1-E5F4-4614-8FAA-238F8C05D1B1Q36718459-12302B87-8616-488D-88C3-F5F1BA6B1A22Q37008863-86668F4E-BAEA-4F24-8A74-C27657609477Q37208764-076292DB-475B-46D5-8BE0-A8C7DE722F44Q37412557-EABAC45E-DB56-4081-BCED-35D439BA8F9CQ37500101-4692016D-595D-4FFC-BB72-D532B881956DQ38104568-140CF72E-8AD3-4425-B690-F534DDA550A9Q38235713-459389FE-9565-4432-9C4C-7BD067BA9FADQ41840697-A4FDC0DF-C444-4F16-B49E-6E5305FC6E58Q42985583-B6AD7E8D-BE7A-4BFF-A467-59FD099CE7DDQ43592584-5C7F7460-BDB6-4AA9-B9C6-BF1B830DD59EQ43796802-C4764E34-11B0-4D08-AEA2-E1B33EBA80BAQ46246572-06871EBC-A387-4A59-8234-5B2A47FA982DQ46601899-FAD9DC4E-5B8C-453A-B3FA-DC13047A47F8Q49678698-6FF20218-A5FE-4994-8038-37164EF6B75DQ52688051-F6C9C1AD-9CF0-4E79-8AE9-168E9C8C7716Q54378040-9CB52077-2898-47F6-8B1B-F58F48679051Q59127370-B11B95E5-D804-49F7-925D-87B876404DA4
P2860
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Systematic review of taxane-co ...... atment of early breast cancer.
@ast
Systematic review of taxane-co ...... atment of early breast cancer.
@en
type
label
Systematic review of taxane-co ...... atment of early breast cancer.
@ast
Systematic review of taxane-co ...... atment of early breast cancer.
@en
prefLabel
Systematic review of taxane-co ...... atment of early breast cancer.
@ast
Systematic review of taxane-co ...... atment of early breast cancer.
@en
P2093
P1433
P1476
Systematic review of taxane-co ...... atment of early breast cancer.
@en
P2093
A Hamilton
M R Stockler
N R C Wilcken
P304
P356
10.1016/S1470-2045(04)01494-9
P577
2004-06-01T00:00:00Z